Neurogene Inc. Finance Lease, Weighted Average Discount Rate, Percent
Neurogene Inc. (NGNE) had Finance Lease, Weighted Average Discount Rate, Percent of 10.20% as of 2025-12-31, per its 10-K filed 2026-03-24.
Financial Statements › Notes › Leases
us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent · last filed 2026-03-24
- 2025-12-31: Finance Lease, Weighted Average Discount Rate, Percent 10.20%.
- 2024-12-31: Finance Lease, Weighted Average Discount Rate, Percent 11.04%.
- 2024-09-30: Finance Lease, Weighted Average Discount Rate, Percent 11.05%.
- 2024-06-30: Finance Lease, Weighted Average Discount Rate, Percent 11.05%.
| Period end | Finance Lease, Weighted Average Discount Rate, Percent | Finance Lease, Weighted Average Discount Rate, Percent as first filed |
|---|---|---|
| 2025-12-31 | 10.20% 10-K · filed 2026-03-24 | |
| 2024-12-31 | 11.04% 10-K · filed 2026-03-24 | |
| 2024-09-30 | 11.05% 10-Q · filed 2024-11-18 | |
| 2024-06-30 | 11.05% 10-Q · filed 2024-08-09 | |
| 2024-03-31 | 11.49% 10-Q · filed 2024-05-10 | |
| 2023-12-31 | 11.49% 10-K · filed 2025-03-24 | |
| 2022-12-31 | 11.45% 10-K · filed 2024-03-18 | 6.99% 10-K · filed 2023-03-20 |
| 2021-12-31 | 6.98% 10-K · filed 2023-03-20 | |
| 2020-12-31 | 7.11% 10-K · filed 2022-03-01 | |
| 2020-03-31 | 7.11% 10-Q · filed 2020-05-06 | |
| 2019-12-31 | 7.11% 10-K · filed 2021-03-25 | |
| 2019-03-31 | 6.94% 10-Q · filed 2020-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |